immune markerers: CD4, CD4/CD8, NK-cell-activity: significant ↑     GLQ-8* sum No difference   Spitzer uniscale* No data QLQ C-30* No difference <0.05 JNJ-26481585 datasheet   Semiglasov 2004 [57]     CMF, Lektinol 15 ng ML (65)       GLQ-8* sum Superior 60,8mm   Spitzer uniscale* Superior 16,4 mm             CMF, Lektinol 35 ng ML (64)       GLQ-8* sum No difference

  Spitzer uniscale* No data             CMF, placebo (66)                       IIIA–IIIB Iscador (17)       Self-regulation questionnaire (score 1–6)   2.92 → 3.7   0.13   Grossarth 2001a [59]     None (17)           2.87 → 2.99           IV Iscador spezial (20)       Spitzer score questionnaire   ~5 → 7.2   <0.05   Borrelli 2001 [58]     Placebo (10)           ~5.2 → 4.8           Advanced VEC, Eurixor (21) Leukopenia ↓ Platelets: no difference   ≤ 0.001 QoL index* (superior)   Anxienty scale* (superior)   ≤ 0.01   Heiny 1991 [61]     VEC, placebo (19)                     Breast, others All stages Iscador (39)       Self-regulation questionnaire (score 1–6)   3.41 → 3.87   0.02   Grossarth

2001b [59]     None (39)           3.85 → 3.62         Breast, ovary, lung T1–4, N0–3, M0–1 ChemotherapyI, Helixor A (115) Chemotherapy-related adverse events 28 not shown FLIC-score* ↑ 9 TCM-score* ↑ -1   KPS* increase in % of patients 50% FLIC 0.014 TCM 0.0007 KPS 0.002   Piao 2004 [56]     ChemotherapyI, Lentinan MRT67307 in vivo (109) Chemotherapy-related adverse events 77   FLIC-score* ↑ 4,7 TCM-score* 0   KPS* increase in % of patients

32%       Ovary IA–IC Iscador (21)       Self-regulation questionnaire, (score 1–6) median difference   0.58 0.0002 0.30–0.90 Grossarth 2007a [50]     None (21)                     Ovary, others Inoperable Radiation, cisplatin, holoxan, Helixor (23) Nausea ↓, vomiting ↓, depression of leucopoiesis ↓   0.005, 0.08, 0.003 KPS* 67% → 76% (p = 0.0008II) ADP ribosylation factor     not shown   Lange 1985 [63]     Radiation, cisplatin, holoxan (21)         70% → 74% (p = 0.12II)           Cervix IVA-B Iscador (19)       Self-regulation questionnaire, (score 1–6) median difference 0.7   0.014 0.15–1.05 Grossarth 2007c [51]     None (19)                     Uterus IA-C Iscador (30)       Self-regulation questionnaire, (score 1–6) median difference 0.4   0.0012 0.15–0.70 Grossarth 2008a [49]     None (30)                     Non-randomized controlled studies Breast T1–3, N0, M0 Iscador (84)       Self-regulation questionnaire Hazard-ratio 0.20   0.031 0.00–0.35 Grossarth 2006b [52, 53]     None (84)                       I–II AZD0156 chemical structure Surgery, CMF/EC, Iscador (33) CMF/EC-induced lymphocyte decrease ↑, platelet decrease ↓ n.s, 0.01 EORTC QLQ-C30*, BR 23* Reduced increase of nausea/vomiting, general side effects of CMF/EC   0.02 0.